iSpecimen (ISPC) AI Stock Analysis

• Market Cap: $4.93M
• Dividend Yield: N/A
• Average Volume (3M): 204.52K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.04
• Revenue Growth: -13.05%
• EPS Growth: 49.76%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.71
• Shares Outstanding: 3,979,517
• 10 Day Avg. Volume: 432,371
• 30 Day Avg. Volume: 204,523
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.35
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: 0.06
• Enterprise Value/Gross Profit: 0.89
• Enterprise Value/Ebitda: -0.07
• 1Y Price Target: $1.00
• Price Target Upside: -22.48% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: $1.50 ▲(16.28%Upside)

iSpecimen's overall stock score is driven by significant financial challenges, including declining revenue and profitability. While technical indicators show some positive momentum, the company's valuation and compliance issues weigh heavily. Recent capital raising provides some relief but is offset by the Nasdaq non-compliance risk.

iSpecimen Business Overview & Revenue Model

Company Description

iSpecimen Inc. (ISPC) is a technology-driven company operating in the healthcare sector, specializing in the procurement and distribution of human biospecimens. The company provides a centralized marketplace that connects researchers with a diverse network of healthcare providers and biobanks. iSpecimen's platform streamlines the process of sourcing, managing, and delivering biological samples, which are critical for advancing medical research and development.

How the Company Makes Money

iSpecimen makes money primarily through its marketplace platform, which facilitates the procurement of human biospecimens for research purposes. The company generates revenue by charging fees for matching researchers with biospecimen suppliers and for providing logistical services in the collection and delivery of specimens. Additionally, iSpecimen may earn through subscription or transaction-based models with its partners in the healthcare and biobanking sectors. Strategic partnerships with healthcare institutions and biobanks further enhance its revenue-generating capabilities by expanding its access to a wide range of sample types and increasing the platform's attractiveness to researchers.

iSpecimen Financial Statement Overview

Summary

iSpecimen faces significant financial challenges, including declining revenues, negative profitability, and cash flow issues. Despite some improvements in the balance sheet with reduced debt levels and improved equity ratios, the company's financial health remains weak, with persistent net losses and cash flow deficits. Strategic improvements are essential to stabilize and enhance financial performance.

Income Statement

The company has shown a declining trend in revenue and profitability. Gross Profit Margin decreased from 52.8% in 2020 to 42.9% in 2024. Net Profit Margins remain negative, with worsening EBIT and EBITDA margins, indicating operational inefficiency. Revenue has been declining from $11.13 million in 2021 to $9.29 million in 2024, showcasing negative growth.

Balance Sheet

The balance sheet reflects a relatively high level of debt with a Debt-to-Equity Ratio of 0.09 in 2024, reduced from previous years. However, the negative equity in prior years raises concerns about financial stability. The equity ratio improved to 35.4% in 2024 from negative figures in earlier years, indicating some improvement in financial health.

Cash Flow

The company has consistently negative operating and free cash flows, with a significant cash burn. The operating cash flow to net income ratio is negative, highlighting issues in converting income into cash. Although free cash flow improved slightly in 2024 compared to previous years, it remains negative, indicating continued challenges in liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.29M	9.93M	10.40M	11.14M	8.18M
Gross Profit	3.99M	5.11M	5.65M	5.89M	4.60M
EBITDA	-12.73M	-9.10M	-8.80M	-5.86M	-1.74M
Net Income	-12.50M	-11.10M	-9.04M	-10.02M	-6.76M
Balance Sheet
Total Assets	9.35M	15.82M	24.62M	35.72M	6.21M
Cash, Cash Equivalents and Short-Term Investments	1.88M	5.01M	15.31M	27.74M	695.91K
Total Debt	312.17K	196.24K	185.85K	3.42M	12.77M
Total Liabilities	6.04M	6.08M	4.31M	5.93M	33.49M
Stockholders Equity	3.31M	9.74M	20.31M	29.79M	-27.28M
Cash Flow
Free Cash Flow	-8.30M	-10.55M	-9.01M	-11.71M	-1.39M
Operating Cash Flow	-8.26M	-5.81M	-5.82M	-10.67M	-288.38K
Investing Cash Flow	1.98M	-7.23M	-3.19M	-1.04M	-1.10M
Financing Cash Flow	5.82M	70.89K	-3.42M	38.75M	2.03M

iSpecimen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Positive. The current price of 1.29 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 1.09, and below the 200-day MA of 2.19, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 61.73 is Neutral, neither overbought nor oversold. The STOCH value of 70.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ISPC.

iSpecimen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	HK$17.40B	5.81	-7.44%	3.53%	11.55%	-28.15%
AWHL	48 Neutral	$6.21M	―		―	3.53%	52.86%
ISPC	46 Neutral	$4.93M	―	-265.37%	―	-13.05%	49.76%
APDN	42 Neutral	$2.40M	―	-141.39%	―	-58.46%	47.98%
NDRA	34 Underperform	$3.97M	―	-358.41%	―	―	71.89%
CHEK	26 Underperform	$4.33M	―	-74.17%	―	―	―

iSpecimen Corporate Events

iSpecimen Completes Public Offering to Raise $4 Million

On July 23, 2025, iSpecimen Inc. entered into an underwriting agreement with WestPark Capital, Inc. to sell 5,714,283 securities in an underwritten public offering, closing on July 25, 2025. The offering raised approximately $4 million in gross proceeds, with net proceeds of around $3.53 million, which the company plans to use for marketing, a software purchase, and general corporate purposes. The offering enhances iSpecimen’s financial resources, potentially strengthening its market position and operational capabilities.

iSpecimen Appoints Anthony Lau to Board of Directors

On June 18, 2025, Richard J. Paolone and John L. Brooks III resigned from the Board of Directors of iSpecimen Inc., with no disagreements cited regarding company operations or policies. Subsequently, on June 20, 2025, Anthony Lau was appointed to the Board, bringing extensive experience in corporate governance and financial oversight, which is expected to enhance the company’s governance and oversight capabilities.

iSpecimen Faces Nasdaq Non-Compliance Notice

On June 4, 2025, iSpecimen Inc. received a notification from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market, as their equity was reported at $1,668,513. The company has 45 days to submit a compliance plan, and if accepted, may receive an extension of up to 180 days to meet the listing criteria, although there is no guarantee of acceptance or compliance.